TY - JOUR T1 - Cytoprotective Efficacy and Mechanisms of the Liposoluble Iron Chelator 2,2′-Dipyridyl in the Rat Photothrombotic Ischemic Stroke Model JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 1080 LP - 1087 DO - 10.1124/jpet.104.072744 VL - 311 IS - 3 AU - C. Demougeot AU - M. Van Hoecke AU - N. Bertrand AU - A. Prigent-Tessier AU - C. Mossiat AU - A. Beley AU - C. Marie Y1 - 2004/12/01 UR - http://jpet.aspetjournals.org/content/311/3/1080.abstract N2 - We examined the efficacy of the liposoluble iron chelator 2,2′-dipyridyl (DP) in reducing histological damage in rats submitted to cerebral ischemia and the mechanisms involved in the potential cytoprotection. For this purpose, DP (20 mg/kg, i.p.) was administered 15 min before and 1 h after induction of cortical photothrombotic vascular occlusion in rat. Histological studies were performed to assess infarct volume (at days 1 and 3 postischemia) and astromicroglial activation (at day 3 postischemia). Damage to endothelial and neuronal cells was evaluated at day 1 postischemia by quantitative measurements of Evans Blue extravasation and N-acetylaspartate levels, respectively. Cerebral blood flow was recorded in the ischemic core by laser-Doppler flowmetry within the 15 min to 2 h period after photothrombosis. At 4-h postischemia, radical oxygen species (ROS) production was evaluated by measuring brain glutathione concentrations. The cortical expression of the proteins heme oxygenase-1 (HO-1) and hypoxia-inducible factor-1α (HIF-1α) was analyzed by Western blotting at day 1 postischemia. Infarct volume and ischemic damage to endothelial and neuronal cells were significantly reduced by DP treatment. This cytoprotection was associated with a reduction in ROS production, perfusion deficits, and astrocytic activation. DP treatment also resulted in significant changes in HO-1 (+100%) and HIF-1α (–50%) protein expression at the level of the ischemic core. These results report the efficacy of the liposoluble iron chelator DP in reducing histological damage induced by permanent focal ischemia. The American Society for Pharmacology and Experimental Therapeutics ER -